tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A
. 2024 Mar 5;121(10):e2313681121.
doi: 10.1073/pnas.2313681121. Epub 2024 Feb 26. Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform
Soojeong Chang[SUP] 1 [/SUP], Kwang-Soo Shin[SUP] 1 [/SUP], Bongju Park[SUP] 1 [/SUP], Seowoo Park[SUP] 1 [/SUP], Jieun Shin[SUP] 1 [/SUP], Hyemin Park[SUP] 1 [/SUP], In Kyung Jung[SUP] 1 [/SUP], Jong Heon Kim[SUP] 1 [/SUP], Seong Eun Bae[SUP] 2 [/SUP], Jae-Ouk Kim[SUP] 2 [/SUP], Seung Ho Baek[SUP] 3 [/SUP], Green Kim[SUP] 3 [/SUP], Jung Joo Hong[SUP] 3 4 [/SUP], Hyungseok Seo[SUP] 5 [/SUP], Erik Volz[SUP] 6 [/SUP], Chang-Yuil Kang[SUP] 1 [/SUP]
Affiliations
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron strain has evolved into highly divergent variants with several sub-lineages. These newly emerging variants threaten the efficacy of available COVID-19 vaccines. To mitigate the occurrence of breakthrough infections and re-infections, and more importantly, to reduce the disease burden, it is essential to develop a strategy for producing updated multivalent vaccines that can provide broad neutralization against both currently circulating and emerging variants. We developed bivalent vaccine AdCLD-CoV19-1 BA.5/BA.2.75 and trivalent vaccines AdCLD-CoV19-1 XBB/BN.1/BQ.1.1 and AdCLD-CoV19-1 XBB.1.5/BN.1/BQ.1.1 using an Ad5/35 platform-based non-replicating recombinant adenoviral vector. We compared immune responses elicited by the monovalent and multivalent vaccines in mice and macaques. We found that the BA.5/BA.2.75 bivalent and the XBB/BN.1/BQ.1.1 and XBB.1.5/BN.1/BQ.1.1 trivalent vaccines exhibited improved cross-neutralization ability compared to their respective monovalent vaccines. These data suggest that the developed multivalent vaccines enhance immunity against circulating Omicron subvariants and effectively elicit neutralizing antibodies across a broad spectrum of SARS-CoV-2 variants.
Keywords: COVID-19 vaccine; SARS-CoV-2 variants; chimeric adenovirus-vectored vaccine; multivalent vaccine; neutralizing activity.
. 2024 Mar 5;121(10):e2313681121.
doi: 10.1073/pnas.2313681121. Epub 2024 Feb 26. Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform
Soojeong Chang[SUP] 1 [/SUP], Kwang-Soo Shin[SUP] 1 [/SUP], Bongju Park[SUP] 1 [/SUP], Seowoo Park[SUP] 1 [/SUP], Jieun Shin[SUP] 1 [/SUP], Hyemin Park[SUP] 1 [/SUP], In Kyung Jung[SUP] 1 [/SUP], Jong Heon Kim[SUP] 1 [/SUP], Seong Eun Bae[SUP] 2 [/SUP], Jae-Ouk Kim[SUP] 2 [/SUP], Seung Ho Baek[SUP] 3 [/SUP], Green Kim[SUP] 3 [/SUP], Jung Joo Hong[SUP] 3 4 [/SUP], Hyungseok Seo[SUP] 5 [/SUP], Erik Volz[SUP] 6 [/SUP], Chang-Yuil Kang[SUP] 1 [/SUP]
Affiliations
- PMID: 38408238
- DOI: 10.1073/pnas.2313681121
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron strain has evolved into highly divergent variants with several sub-lineages. These newly emerging variants threaten the efficacy of available COVID-19 vaccines. To mitigate the occurrence of breakthrough infections and re-infections, and more importantly, to reduce the disease burden, it is essential to develop a strategy for producing updated multivalent vaccines that can provide broad neutralization against both currently circulating and emerging variants. We developed bivalent vaccine AdCLD-CoV19-1 BA.5/BA.2.75 and trivalent vaccines AdCLD-CoV19-1 XBB/BN.1/BQ.1.1 and AdCLD-CoV19-1 XBB.1.5/BN.1/BQ.1.1 using an Ad5/35 platform-based non-replicating recombinant adenoviral vector. We compared immune responses elicited by the monovalent and multivalent vaccines in mice and macaques. We found that the BA.5/BA.2.75 bivalent and the XBB/BN.1/BQ.1.1 and XBB.1.5/BN.1/BQ.1.1 trivalent vaccines exhibited improved cross-neutralization ability compared to their respective monovalent vaccines. These data suggest that the developed multivalent vaccines enhance immunity against circulating Omicron subvariants and effectively elicit neutralizing antibodies across a broad spectrum of SARS-CoV-2 variants.
Keywords: COVID-19 vaccine; SARS-CoV-2 variants; chimeric adenovirus-vectored vaccine; multivalent vaccine; neutralizing activity.